273 related articles for article (PubMed ID: 23686260)
1. HMGA2 and high-grade serous ovarian carcinoma.
Wu J; Wei JJ
J Mol Med (Berl); 2013 Oct; 91(10):1155-65. PubMed ID: 23686260
[TBL] [Abstract][Full Text] [Related]
2. HMGA2 overexpression-induced ovarian surface epithelial transformation is mediated through regulation of EMT genes.
Wu J; Liu Z; Shao C; Gong Y; Hernando E; Lee P; Narita M; Muller W; Liu J; Wei JJ
Cancer Res; 2011 Jan; 71(2):349-59. PubMed ID: 21224353
[TBL] [Abstract][Full Text] [Related]
3. STC2 overexpression mediated by HMGA2 is a biomarker for aggressiveness of high-grade serous ovarian cancer.
Wu J; Lai M; Shao C; Wang J; Wei JJ
Oncol Rep; 2015 Sep; 34(3):1494-502. PubMed ID: 26165228
[TBL] [Abstract][Full Text] [Related]
4. Expression analysis of MIR182 and its associated target genes in advanced ovarian carcinoma.
McMillen BD; Aponte MM; Liu Z; Helenowski IB; Scholtens DM; Buttin BM; Wei JJ
Mod Pathol; 2012 Dec; 25(12):1644-53. PubMed ID: 22790015
[TBL] [Abstract][Full Text] [Related]
5. [Overexpression of high mobility group A2 and its correlation with microRNA let-7 family in serous ovarian cancers].
Yang J; Zhang Q; Dong JQ; Chang XH; He XJ
Beijing Da Xue Xue Bao Yi Xue Ban; 2012 Oct; 44(5):749-54. PubMed ID: 23073586
[TBL] [Abstract][Full Text] [Related]
6. MiR-182 overexpression in tumourigenesis of high-grade serous ovarian carcinoma.
Liu Z; Liu J; Segura MF; Shao C; Lee P; Gong Y; Hernando E; Wei JJ
J Pathol; 2012 Oct; 228(2):204-15. PubMed ID: 22322863
[TBL] [Abstract][Full Text] [Related]
7. HMGA2: a biomarker significantly overexpressed in high-grade ovarian serous carcinoma.
Mahajan A; Liu Z; Gellert L; Zou X; Yang G; Lee P; Yang X; Wei JJ
Mod Pathol; 2010 May; 23(5):673-81. PubMed ID: 20228781
[TBL] [Abstract][Full Text] [Related]
8. Shortening of the 3' untranslated region: an important mechanism leading to overexpression of HMGA2 in serous ovarian cancer.
He X; Yang J; Zhang Q; Cui H; Zhang Y
Chin Med J (Engl); 2014; 127(3):494-9. PubMed ID: 24451956
[TBL] [Abstract][Full Text] [Related]
9. MYC-regulated pseudogene HMGA1P6 promotes ovarian cancer malignancy via augmenting the oncogenic HMGA1/2.
Tian X; Song J; Zhang X; Yan M; Wang S; Wang Y; Xu L; Zhao L; Wei JJ; Shao C; Kong B; Liu Z
Cell Death Dis; 2020 Mar; 11(3):167. PubMed ID: 32127525
[TBL] [Abstract][Full Text] [Related]
10. A 2-Protein Signature Predicting Clinical Outcome in High-Grade Serous Ovarian Cancer.
Jin C; Xue Y; Li Y; Bu H; Yu H; Zhang T; Zhang Z; Yan S; Lu N; Kong B
Int J Gynecol Cancer; 2018 Jan; 28(1):51-58. PubMed ID: 28976449
[TBL] [Abstract][Full Text] [Related]
11. MiR-219-5p inhibits growth and metastasis of ovarian cancer cells by targeting HMGA2.
Xing F; Song Z; He Y
Biol Res; 2018 Nov; 51(1):50. PubMed ID: 30474570
[TBL] [Abstract][Full Text] [Related]
12. ROR2 induces cell apoptosis via activating IRE1α/JNK/CHOP pathway in high-grade serous ovarian carcinoma in vitro and in vivo.
Li R; Liu T; Shi J; Luan W; Wei X; Yu J; Mao H; Liu P
J Transl Med; 2019 Dec; 17(1):428. PubMed ID: 31878941
[TBL] [Abstract][Full Text] [Related]
13. ZEB2 facilitates peritoneal metastasis by regulating the invasiveness and tumorigenesis of cancer stem-like cells in high-grade serous ovarian cancers.
Li Y; Fei H; Lin Q; Liang F; You Y; Li M; Wu M; Qu Y; Li P; Yuan Y; Chen T; Jiang H
Oncogene; 2021 Aug; 40(32):5131-5141. PubMed ID: 34211089
[TBL] [Abstract][Full Text] [Related]
14. HMGA2 protein expression in ovarian serous carcinoma effusions, primary tumors, and solid metastases.
Hetland TE; Holth A; Kærn J; Flørenes VA; Tropé CG; Davidson B
Virchows Arch; 2012 May; 460(5):505-13. PubMed ID: 22476403
[TBL] [Abstract][Full Text] [Related]
15. Characterization of MicroRNA-200 pathway in ovarian cancer and serous intraepithelial carcinoma of fallopian tube.
Yang J; Zhou Y; Ng SK; Huang KC; Ni X; Choi PW; Hasselblatt K; Muto MG; Welch WR; Berkowitz RS; Ng SW
BMC Cancer; 2017 Jun; 17(1):422. PubMed ID: 28623900
[TBL] [Abstract][Full Text] [Related]
16. miR-145, targeting high-mobility group A2, is a powerful predictor of patient outcome in ovarian carcinoma.
Kim TH; Song JY; Park H; Jeong JY; Kwon AY; Heo JH; Kang H; Kim G; An HJ
Cancer Lett; 2015 Jan; 356(2 Pt B):937-45. PubMed ID: 25444913
[TBL] [Abstract][Full Text] [Related]
17. High Mobility Group AT-Hook 2 (HMGA2) Oncogenicity in Mesenchymal and Epithelial Neoplasia.
Unachukwu U; Chada K; D'Armiento J
Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32365712
[TBL] [Abstract][Full Text] [Related]
18. The role of distinct BRD4 isoforms and their contribution to high-grade serous ovarian carcinoma pathogenesis.
Drumond-Bock AL; Bieniasz M
Mol Cancer; 2021 Nov; 20(1):145. PubMed ID: 34758842
[TBL] [Abstract][Full Text] [Related]
19. Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver.
Emmanuel C; Chiew YE; George J; Etemadmoghadam D; Anglesio MS; Sharma R; Russell P; Kennedy C; Fereday S; Hung J; Galletta L; Hogg R; Wain GV; Brand A; Balleine R; MacConaill L; Palescandolo E; Hunter SM; Campbell I; Dobrovic A; Wong SQ; Do H; Clarke CL; Harnett PR; Bowtell DD; deFazio A;
Clin Cancer Res; 2014 Dec; 20(24):6618-30. PubMed ID: 25316818
[TBL] [Abstract][Full Text] [Related]
20. Early Loss of Histone H2B Monoubiquitylation Alters Chromatin Accessibility and Activates Key Immune Pathways That Facilitate Progression of Ovarian Cancer.
Hooda J; Novak M; Salomon MP; Matsuba C; Ramos RI; MacDuffie E; Song M; Hirsch MS; Lester J; Parkash V; Karlan BY; Oren M; Hoon DS; Drapkin R
Cancer Res; 2019 Feb; 79(4):760-772. PubMed ID: 30563893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
